Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"MinervaX","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","amount":"$56.8 million","upfrontCash":"Undisclosed","newsHeadline":"MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for Aluminum

    Menu

    Aluminum

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    MARKET PLACE

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              MinervaX

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus

              Details:

              This financing will enable MinervaX to progress its novel GBS vaccine GBS-NN/NN2, towards Phase III clinical trials in 2024. The Company is currently progressing two Phase II clinical trials in 470 pregnant persons across Denmark, United Kingdom, Uganda and South Africa.

              Lead Product(s): GBS-NN,Aluminum

              Therapeutic Area: Infections and Infectious Diseases Product Name: GBS-NN/NN2

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: EQT Life Sciences

              Deal Size: $56.8 million Upfront Cash: Undisclosed

              Deal Type: Financing October 11, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY